Copertina

Interplay between α‐thalassemia and β‐hemoglobinopathies: Translating genotype–phenotype relationships into therapies

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jim Vadolas, Tiwaporn Nualkaew, Hsiao P. J. Voon, Shahla Vilcassim, George Grigoriadis
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	HemaSphere
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Splenectomy in β‐thalassemia patients: Practices and risks in a nationwide study
di: Audrey Benoit, et al.
Pubblicazione: (2026)

Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?
di: Khaled M. Musallam, et al.
Pubblicazione: (2025)

Accurate diagnosis of hemoglobinopathies with machine learning based on high‐throughput proteomics
di: Shaodong Wei, et al.
Pubblicazione: (2025)

HELIOS Action: Advancing research, education, and equity in hemoglobinopathies across Europe and beyond
di: Sotiroula Chatzimatthaiou, et al.
Pubblicazione: (2025)

How I manage luspatercept in transfusion‐dependent beta‐thalassemia
di: Daniele Lello Panzieri, et al.
Pubblicazione: (2026)

Cerebral hemodynamics and oxygen metabolism in patients with milder and severe forms of sickle cell disease and thalassemia
di: Liza Afzali‐Hashemi, et al.
Pubblicazione: (2024)

Expanding the phenotypic and genetic landscape of congenital neutropenia through whole‐exome and genome sequencing
di: Séverine Marti, et al.
Pubblicazione: (2025)

Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype
di: Francesco Rodeghiero, et al.
Pubblicazione: (2025)

Can health inequalities in sickle cell disease be addressed through novel therapies?
di: Stephen P. Hibbs, et al.
Pubblicazione: (2025)

Cellular therapies for sickle cell disease: Should we be calling them a cure?
di: Lydia O. Okoibhole, et al.
Pubblicazione: (2025)

TIF Guidelines for the Management of Transfusion‐Dependent β‐Thalassemia
di: Khaled M. Musallam, et al.
Pubblicazione: (2025)

A single‐center cohort study of patients with hereditary spherocytosis in Central Europe reveals a high frequency of novel disease‐causing genotypes
di: Leo Kager, et al.
Pubblicazione: (2024)

In vivo CAR therapies: Turning the patient into their own CAR factory
di: François Vilcot, et al.
Pubblicazione: (2026)

Inflammatory pathways and anti‐inflammatory therapies in sickle cell disease
di: Karina Tozatto‐Maio, et al.
Pubblicazione: (2024)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
di: Raúl Córdoba, et al.
Pubblicazione: (2026)

New approaches in gene therapy for sickle cell disease, moving in vivo
di: David G. Kent
Pubblicazione: (2024)

Response to therapy and prognosis according to molecular characterization in CALR ‐mutated essential thrombocythemia
di: Marta Santaliestra, et al.
Pubblicazione: (2026)

Correction to “New approaches in gene therapy for sickle cell disease, moving in vivo”
Pubblicazione: (2024)

Oncogenic and immunological targets for matched therapy of pediatric blood cancer patients: Dutch iTHER study experience
di: Judith M. Boer, et al.
Pubblicazione: (2024)

Preliminary evidence of CAR T‐cell therapy activity in vitreoretinal lymphomas: An LOC network study
di: Cécile Pivert, et al.
Pubblicazione: (2025)

Cell surface surprise: NPM1 is an immune therapy target for acute myeloid leukemia
di: Hansen J. Kosasih, et al.
Pubblicazione: (2025)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
di: Patrick Born, et al.
Pubblicazione: (2025)

Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patients
di: Caroline Diorio, et al.
Pubblicazione: (2026)

Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD‐1 blockade
di: Thomas M. Kuczmarski, et al.
Pubblicazione: (2025)

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR‐T therapy
di: Lukas Scheller, et al.
Pubblicazione: (2025)

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?
di: Baptiste Le Calvez, et al.
Pubblicazione: (2024)

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
di: Ola Landgren, et al.
Pubblicazione: (2025)

Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma
di: Inna Y. Gong, et al.
Pubblicazione: (2024)

Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
di: Uwe Platzbecker, et al.
Pubblicazione: (2025)

Bridging gaps in clinical trial accessibility and reimbursement for large B‐cell lymphoma therapies across Europe
di: Florence Broussais, et al.
Pubblicazione: (2025)

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first‐line therapy irrespective of frailty levels
di: Wassilis S. C. Bruins, et al.
Pubblicazione: (2025)

Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy
di: Gloria Iacoboni, et al.
Pubblicazione: (2024)

High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
di: Andrea Manubens, et al.
Pubblicazione: (2025)

High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma
di: Maeve A. O'Reilly, et al.
Pubblicazione: (2024)

Efficacy of anti‐PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA
di: Amira Marouf, et al.
Pubblicazione: (2025)

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
di: Sophia Stock, et al.
Pubblicazione: (2025)

Efficacy and safety of bendamustine‐containing bridging therapy in R/R LBCL patients receiving CD19 CAR T‐cells
di: Gloria Iacoboni, et al.
Pubblicazione: (2024)

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy
di: Austin Kulasekararaj, et al.
Pubblicazione: (2026)

Mitigation of atrial fibrillation‐related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG‐MPN bioregistry
di: Hyunyee Rosa Cho, et al.
Pubblicazione: (2025)

Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition
di: Anna Ossami Saidy, et al.
Pubblicazione: (2025)